A recent study reported that AhR activity suppresses STImulator of Interferon Genes (STING) mediated type I interferon (IFN-I) expression in TNBC cell lines and that AhR could potentially represent a feasible therapeutic strategy to enhance the immunogenicity of TNBC tumours [20]. The gene discussed is AHR; the disease is neoplasm.